GLORIA MCMILLAN: Open Payments
NPI 1205136363 · BURLINGTON, IA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,100 in 131 payments from 13 companies in 2025. Trend: 2023 $1,296 · 2024 $1,840 · 2025 $2,100
Food & beverage: $2,100
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $321 |
| Vanda Pharmaceuticals Inc. | 12 | $270 |
| ABBVIE INC. | 25 | $265 |
| Otsuka America Pharmaceutical, Inc. | 13 | $239 |
| Lundbeck LLC | 21 | $228 |
| Janssen Pharmaceuticals, Inc | 12 | $218 |
| Neurocrine BioSciences, Inc. | 9 | $163 |
| E.R. Squibb & Sons, L.L.C. | 13 | $159 |
| Teva Pharmaceuticals USA, Inc. | 4 | $74 |
| Alkermes, Inc. | 4 | $65 |
Products named: CAPLYTA, REXULTI, FANAPT, VRAYLAR, INVEGA SUSTENNA, INGREZZA, COBENFY, ABILIFY MAINTENA.
Industry payments across IA — which companies pay providers there.
